Barbara Duncan

Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues.

DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ.

Edgemont Pharmaceuticals LLC develops and provides products for psychiatric disorders. The company was founded by Douglas A. Saltel in 2008 and is headquartered in Austin, TX.

Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY.

Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million.

Part of Halozyme Therapeutics, Inc., Halozyme, Inc. is a company based in San Diego, CA.